Health Catalyst, Inc. (HCAT) Stock Forecast
Data as of Jun 17, 2026Healthcare · Current price $1.76 (-0.84%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 13, 2026 | Sarah James | Raymond James | $3.00 | +70.5% |
| Mar 13, 2026 | Richard Close | Canaccord Genuity | $2.00 | +13.6% |
| Aug 29, 2025 | Richard Close | Canaccord Genuity | $5.00 | +184.1% |
| Apr 16, 2025 | Scott Schoenhaus | KeyBanc | $5.00 | +184.1% |
| Jan 14, 2025 | Sean Dodge | RBC Capital | $7.00 | +297.7% |
| Sep 3, 2024 | Richard Close | Canaccord Genuity | $11.00 | +525.0% |
| Aug 26, 2024 | Jessica Tassan | Piper Sandler | $11.00 | +525.0% |
| Aug 8, 2024 | Jeff Garro | Stephens | $7.00 | +297.7% |
| Jun 6, 2024 | Jessica Tassan | Piper Sandler | $14.00 | +695.5% |
| Jan 26, 2024 | Jack Wallace | Guggenheim | $14.00 | +695.5% |
| May 11, 2022 | Jessica Tassan | Piper Sandler | $21.00 | +1093.2% |
| Mar 2, 2022 | Sean Dodge | RBC Capital | $35.00 | +1888.6% |
| Mar 2, 2022 | Elizabeth Anderson CFA | Evercore ISI | $48.00 | +2627.3% |
| Feb 11, 2022 | Cindy Motz CFA | Goldman Sachs | $48.00 | +2627.3% |
| May 27, 2021 | Sandy Draper | Guggenheim | $60.00 | +3309.1% |
| May 7, 2021 | Steven Halper | Cantor Fitzgerald | $60.00 | +3309.1% |
Top Analysts Covering HCAT
HCAT vs Sector & Market
| Metric | HCAT | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.88 | 2.24 | 2.40 |
| Analyst Count | 8 | 8 | 19 |
| Target Upside | +27.5% | +11475.0% | +17.1% |
| P/E Ratio | -0.53 | 3.91 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $70M | $71M | $72M | 6 |
| 2026-09-30 | $68M | $70M | $72M | 4 |
| 2026-12-31 | $68M | $70M | $72M | 5 |
| 2027-03-31 | $66M | $68M | $70M | 3 |
| 2027-06-30 | $68M | $70M | $72M | 3 |
| 2027-09-30 | $69M | $71M | $73M | 3 |
| 2027-12-31 | $69M | $71M | $73M | 3 |
| 2028-12-31 | $282M | $294M | $304M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $0.03 | $0.03 | $0.03 | 4 |
| 2026-09-30 | $0.03 | $0.03 | $0.03 | 1 |
| 2026-12-31 | $0.04 | $0.04 | $0.04 | 2 |
| 2027-03-31 | $0.03 | $0.03 | $0.03 | 2 |
| 2027-06-30 | $0.04 | $0.04 | $0.04 | 1 |
| 2027-09-30 | $0.04 | $0.04 | $0.04 | 1 |
| 2027-12-31 | $0.05 | $0.05 | $0.05 | 2 |
| 2028-12-31 | $0.22 | $0.23 | $0.24 | 1 |
Frequently Asked Questions
What is the analyst consensus for HCAT?
The consensus among 8 analysts covering Health Catalyst, Inc. (HCAT) is Hold with an average price target of $2.25.
What is the highest price target for HCAT?
The highest price target for HCAT is $60.00, set by Sandy Draper at Guggenheim on 2021-05-27.
What is the lowest price target for HCAT?
The lowest price target for HCAT is $2.00, set by Richard Close at Canaccord Genuity on 2026-03-13.
How many analysts cover HCAT?
8 analysts have issued ratings for Health Catalyst, Inc. in the past 12 months.
Is HCAT a buy or sell right now?
Based on 8 analyst ratings, HCAT has a consensus rating of Hold (2.88/5) with a +27.5% upside to the consensus target of $2.25.
What are the earnings estimates for HCAT?
Analysts estimate HCAT will report EPS of $0.03 for the period ending 2026-06-30, with revenue estimated at $71M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.